Nathan Levitan

4.3k total citations · 2 hit papers
40 papers, 3.2k citations indexed

About

Nathan Levitan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Nathan Levitan has authored 40 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Epidemiology. Recurrent topics in Nathan Levitan's work include Lung Cancer Research Studies (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Neuroendocrine Tumor Research Advances (7 papers). Nathan Levitan is often cited by papers focused on Lung Cancer Research Studies (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Neuroendocrine Tumor Research Advances (7 papers). Nathan Levitan collaborates with scholars based in United States, Canada and United Kingdom. Nathan Levitan's co-authors include Mark Allen O’Rourke, J. Bérille, Rodryg Ramlau, Susan Coughlin, Yong Kim, Ronald L. Burkes, Janet Dancey, Richard J. Gralla, Frances A. Shepherd and K. Mattson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Nathan Levitan

40 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2000 1.7k citations Frances A. Shepherd, Janet Dancey et al. Journal of Clinical Oncology profile →
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data

1999 709 citations Nathan Levitan, Afshin Dowlati et al. Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Levitan United States	16	2.0k	1.8k	636	523	446	40	3.2k
Rodolfo Passalacqua Italy	28	1.3k 0.7×	2.1k 1.1×	411 0.6×	948 1.8×	438 1.0×	140	3.7k
V. Bramwell Canada	27	1.6k 0.8×	2.0k 1.1×	324 0.5×	446 0.9×	436 1.0×	67	3.5k
Uwe Pelzer Germany	30	801 0.4×	2.1k 1.2×	469 0.7×	749 1.4×	332 0.7×	135	3.0k
Julie Hambleton United States	17	598 0.3×	1.1k 0.6×	665 1.0×	594 1.1×	556 1.2×	31	3.0k
Sergio Ricci Italy	25	1.2k 0.6×	2.7k 1.5×	420 0.7×	1.9k 3.7×	971 2.2×	62	5.5k
Monique M.E.M. Bos Netherlands	19	667 0.3×	1.1k 0.6×	322 0.5×	203 0.4×	527 1.2×	36	2.1k
Mohammad Jahanzeb United States	21	486 0.2×	855 0.5×	627 1.0×	204 0.4×	190 0.4×	69	1.7k
F. Lofts United Kingdom	18	4.5k 2.3×	1.8k 1.0×	270 0.4×	3.1k 6.0×	545 1.2×	45	6.3k
Xiaolei Zhu China	14	678 0.3×	830 0.5×	235 0.4×	156 0.3×	604 1.4×	35	2.1k
Massimo Magagnoli Italy	26	519 0.3×	1.1k 0.6×	202 0.3×	281 0.5×	108 0.2×	83	2.7k

Countries citing papers authored by Nathan Levitan

Since Specialization

Citations

This map shows the geographic impact of Nathan Levitan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Levitan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Levitan more than expected).

Fields of papers citing papers by Nathan Levitan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Levitan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Levitan. The network helps show where Nathan Levitan may publish in the future.

Co-authorship network of co-authors of Nathan Levitan

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Levitan. A scholar is included among the top collaborators of Nathan Levitan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Levitan. Nathan Levitan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinstein, Elizabeth, et al.. (2021). Quality and cost outcomes of an integrated supportive care program. Supportive Care in Cancer. 30(1). 535–542. 6 indexed citations

Horn, Leora, Patricia Bernardo, Alan Sandler, et al.. (2009). A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group. Journal of Thoracic Oncology. 4(4). 527–533. 13 indexed citations

Phitayakorn, Roy, Nathan Levitan, & Jerry M. Shuck. (2007). Program Report Cards: Evaluation Across Multiple Residency Programs at One Institution. Academic Medicine. 82(6). 608–615. 9 indexed citations

Dowlati, Afshin, Shanmuga Subbiah, Matthew M. Cooney, et al.. (2007). Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer. 56(3). 377–381. 23 indexed citations

Dowlati, Afshin, Robert Chapman, Shanmuga Subbiah, et al.. (2005). Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Investigational New Drugs. 23(6). 563–567. 6 indexed citations

Cooney, Matthew M., Subbiah Shanmugam, Graham Warren, et al.. (2005). Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission. Journal of Clinical Oncology. 23(16_suppl). 7166–7166. 5 indexed citations

Belani, Chandra P., Sudeshna Adak, Seena C. Aisner, et al.. (2004). Docetaxel for Malignant Mesothelioma: Phase II Study of the Eastern Cooperative Oncology Group. Clinical Lung Cancer. 6(1). 43–47. 20 indexed citations

Cooney, Matthew M., Tomas Radivoyevitch, Afshin Dowlati, et al.. (2004). Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer. Clinical Cancer Research. 10(1). 96–100. 103 indexed citations

Dowlati, Afshin & Nathan Levitan. (2003). Combination chemotherapy with topotecan for non-small cell lung cancer. Lung Cancer. 41. S23–S26. 1 indexed citations

10.

Willis, Joseph, Gregory S. Cooper, Gerard Isenberg, et al.. (2002). Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointestinal Endoscopy. 55(6). 655–661. 71 indexed citations

11.

Dowlati, Afshin, Nathan Levitan, Nahida H. Gordon, et al.. (2001). Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 47(2). 141–148. 20 indexed citations

12.

Shepherd, Frances A., Janet Dancey, Rodryg Ramlau, et al.. (2000). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of Clinical Oncology. 18(10). 2095–2103. 1717 indexed citations breakdown →

13.

Levitan, Nathan, et al.. (1999). Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data. Medicine. 78(5). 285–91. 709 indexed citations breakdown →

14.

Dowlati, Afshin, Nathan Levitan, & Scot C. Remick. (1999). Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. Journal of Laboratory and Clinical Medicine. 134(4). 405–409. 23 indexed citations

15.

Isenberg, Gerard, Amitabh Chak, Marcia Irene Canto, et al.. (1998). Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointestinal Endoscopy. 48(2). 158–163. 113 indexed citations

16.

Levitan, Nathan, et al.. (1998). A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. Lung Cancer. 22(3). 227–234. 5 indexed citations

17.

Levitan, Nathan. (1993). Chemotherapy in Colorectal Carcinoma. Surgical Clinics of North America. 73(1). 183–198. 13 indexed citations

18.

Williamson, Warren A., et al.. (1992). Pulmonary Venous Infarction Secondary to Squamous Cell Carcinoma. CHEST Journal. 102(3). 950–952. 4 indexed citations

19.

Williamson, Warren A., et al.. (1992). Pulmonary Venous Infarction. CHEST Journal. 102(3). 937–940. 28 indexed citations

20.

Levitan, Nathan, et al.. (1986). An Autoanalyzer Test for the Quantitation ofPlatelet-Associated IgG. Vox Sanguinis. 51(2). 127–132. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact